NCT04887194 2024-05-08
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
Mirati Therapeutics Inc.
Phase 1 Completed
Mirati Therapeutics Inc.
Jiangsu HengRui Medicine Co., Ltd.
Eli Lilly and Company
Eli Lilly and Company
Bayer
Daiichi Sankyo
GlaxoSmithKline
Astellas Pharma Inc
Spectrum Pharmaceuticals, Inc